IL321857A - פורמולציות rna לשימוש פרמצבטי - Google Patents
פורמולציות rna לשימוש פרמצבטיInfo
- Publication number
- IL321857A IL321857A IL321857A IL32185725A IL321857A IL 321857 A IL321857 A IL 321857A IL 321857 A IL321857 A IL 321857A IL 32185725 A IL32185725 A IL 32185725A IL 321857 A IL321857 A IL 321857A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical use
- rna formulations
- rna
- formulations
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2023/051117 WO2024153324A1 (en) | 2023-01-18 | 2023-01-18 | Rna formulations for pharmaceutical use |
| PCT/EP2024/050983 WO2024153675A1 (en) | 2023-01-18 | 2024-01-17 | Rna formulations for pharmaceutical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL321857A true IL321857A (he) | 2025-08-01 |
Family
ID=85037171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL321857A IL321857A (he) | 2023-01-18 | 2025-06-30 | פורמולציות rna לשימוש פרמצבטי |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4652270A1 (he) |
| JP (1) | JP2026508822A (he) |
| CN (1) | CN120712350A (he) |
| AU (1) | AU2024210882A1 (he) |
| IL (1) | IL321857A (he) |
| WO (2) | WO2024153324A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026061971A1 (en) | 2024-09-17 | 2026-03-26 | Lonza Ltd | Nucleic acid untranslated regions |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| ES2655912T3 (es) | 2002-11-08 | 2018-02-22 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| ES2567634T3 (es) | 2004-02-09 | 2016-04-25 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| WO2008012629A2 (en) | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
| CN101646689A (zh) | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| JP2011507543A (ja) | 2007-12-27 | 2011-03-10 | ノバルティス アーゲー | 改善されたフィブロネクチンベースの結合分子およびそれらの使用 |
| PL2274331T3 (pl) | 2008-05-02 | 2014-04-30 | Novartis Ag | Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie |
| CN102812014B (zh) | 2009-10-30 | 2016-01-20 | 多美恩医疗公司 | 新颖的肟衍生物及其作为代谢型谷氨酸受体的别构调节剂的用途 |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| EA022983B1 (ru) | 2010-04-13 | 2016-04-29 | Бристол-Майерс Сквибб Компани | Белки на основе структурного домена фибронектина, связывающие pcsk9 |
| US20140220017A1 (en) | 2011-09-23 | 2014-08-07 | Universitat Stuttgart | Serum half-life extension using igbd |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| IL307179A (he) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | ליפידים חדשים ופורמולציות ננוחלקיקים של ליפידים למתן חומצות גרעין |
| BR112018069417A2 (pt) | 2016-04-22 | 2019-01-22 | Biontech Rna Pharmaceuticals Gmbh | método para fornecer rna fita simples e ssrna |
| ES3063077T3 (en) | 2016-10-26 | 2026-04-15 | Acuitas Therapeutics Inc | Lipid nanoparticle formulations |
| JP7423521B2 (ja) * | 2017-11-22 | 2024-01-29 | モダーナティエックス・インコーポレイテッド | フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド |
| WO2020047201A1 (en) * | 2018-09-02 | 2020-03-05 | Modernatx, Inc. | Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
| EP4126069A1 (en) | 2020-03-25 | 2023-02-08 | BioNTech SE | Rna particles comprising polysarcosine |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| CA3171589A1 (en) * | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
-
2023
- 2023-01-18 WO PCT/EP2023/051117 patent/WO2024153324A1/en not_active Ceased
-
2024
- 2024-01-17 EP EP24701327.9A patent/EP4652270A1/en active Pending
- 2024-01-17 JP JP2025541953A patent/JP2026508822A/ja active Pending
- 2024-01-17 CN CN202480012929.8A patent/CN120712350A/zh active Pending
- 2024-01-17 AU AU2024210882A patent/AU2024210882A1/en active Pending
- 2024-01-17 WO PCT/EP2024/050983 patent/WO2024153675A1/en not_active Ceased
-
2025
- 2025-06-30 IL IL321857A patent/IL321857A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024153324A1 (en) | 2024-07-25 |
| WO2024153675A1 (en) | 2024-07-25 |
| JP2026508822A (ja) | 2026-03-13 |
| EP4652270A1 (en) | 2025-11-26 |
| AU2024210882A1 (en) | 2025-07-17 |
| CN120712350A (zh) | 2025-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202109102PA (en) | Pharmaceutical formulations | |
| EP4188329A4 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING TADALAFIL | |
| IL321857A (he) | פורמולציות rna לשימוש פרמצבטי | |
| GB202010230D0 (en) | Pharmaceutical formulation | |
| GB202005282D0 (en) | Pharmaceutical Formulations | |
| GB202100526D0 (en) | Pharmaceutical formulation | |
| ZA202212663B (en) | Pharmaceutical formulations | |
| EP4034120A4 (en) | SOLID ORAL PHARMACEUTICAL FORMULATIONS COMPRISING SAPROPTERIN DICHLORHYDRATE AND AT LEAST ONE PHARMACEUTICAL EXCIPIENT | |
| IL307803A (he) | פורמולציות הידרונידון רוקחיות למחלות | |
| IL314206A (he) | פורמולציה תרופתית | |
| HK40128321A (en) | Rna formulations for pharmaceutical use | |
| CA3279723A1 (en) | Rna formulations for pharmaceutical use | |
| GB202003108D0 (en) | Pharmaceutical formulations | |
| GB202001439D0 (en) | Drug formulations | |
| IL314046A (he) | תכשירים תרופתיים של ribociclib | |
| IL297081A (he) | פורמולציה רוקחית | |
| GB202307626D0 (en) | Pharmaceutical formulations | |
| IL308250A (he) | פורמולציות תרופתיות | |
| GB202112820D0 (en) | Pharmaceutical formulations | |
| GB202417264D0 (en) | Pharmaceutical formulations | |
| GB202417258D0 (en) | Pharmaceutical formulations | |
| GB202417250D0 (en) | Pharmaceutical formulations | |
| GB202015273D0 (en) | Solid form pharmaceutical formulations | |
| IL321640A (he) | תכשיר רפואי | |
| IL319214A (he) | פורמולציה רוקחית |